Funded as part of the European Union’s response to the COVID-19 pandemic
Digital therapeutic for metabolic health
We are developing digital therapeutic platform for the prevention and treatment of cardiometabolic diseases.
Project scope
Silent epidemic
Estonia's first prescription digital therapeutic for the prevention and treatment of cardiometabolic diseases.
- The global prevalence of cardiometabolic diseases, including metabolic syndrome is growing fast, affecting nearly a third of the world’s adult population.
- People with metabolic syndrome have 3x higher risk of heart attack and stroke, and 5x higher risk of type 2 diabetes.
- The 2 year project with a budget of 1 million euros will bring together data scientists, engineers and medical experts to develop a novel digital therapeutic (DTx) platform for preventing, monitoring and managing metabolic syndrome.
- The project is funded by the European Regional Development Fund in the amount of 772 500 EUR, in addition to private sector investment by the company.
